Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q1 2023 vs. Q4 2022
How the institutions holding Revelation Biosciences, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 10 | 11 | +1 |
| Shares | 2.24M | 806.1K | −1.44M (−64.0%) |
| Value | $426.9K | $1.05M | +$620.9K (+145.4%) |
New holders (7)
Institutions that held Revelation Biosciences, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 213,509 | $277.6K | 0.09% |
| Sabby Management, LLC | 180,431 | $234.6K | 0.87% |
| Walleye Capital LLC | 174,685 | $227.1K | 0.00% |
| Hudson Bay Capital Management LP | 109,520 | $142.4K | 0.00% |
| Altium Capital Management LP | 37,198 | $48.4K | 0.03% |
| CVI Holdings, LLC | 33,204 | $43.2K | 0.02% |
| UBS Group AG | 1,362 | $1.77K | 0.00% |
Sold out (6)
Institutions that held Revelation Biosciences, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| State Street Corp | 108,828 | $20.9K |
| Rebalance, LLC | 85,844 | $16.3K |
| Two Sigma Securities, LLC | 39,398 | $7.49K |
| Mayflower Financial Advisors, LLC | 21,425 | $4.07K |
| Tower Research Capital LLC (TRC) | 8,472 | $2.00K |
| Valeo Financial Advisors, LLC | 10,000 | $1.90K |